Last updated: 2026-10-13 12:36:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
DaVita Inc. (DVA) operates in the SERVICES-MISC HEALTH & ALLIED SERVICES, NEC sector and is listed on NYSE. The stock is currently priced at $183.98, with a market capitalization of $11.44B and a P/E ratio of 13.68. Over the past 52 weeks, its price has ranged from $101.00 to $247.49. This page covers its latest market performance, valuation, price trends and company information.
$11.44B | |
$181.74 | |
$247.49 | |
$10.22 | |
$181.78 | |
441.00 | |
759.86K | |
13.68 | |
$247.49 | |
$101.00 | |
-- | |
-- |
DaVita Inc. (DVA) is trading at $183.98 in pre-market trading as of 2026-10-13 12:33:00, up 1.21% ($2.19) from the previous close of $181.78
Pre-market trading shows how investors are pricing DVA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, DaVita Inc. (DVA) moved from $178.69 to $183.98, representing a gain of 2.96% ($5.28).
The stock traded between $175.41 and $183.98 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 495.27 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 56.6%
DVA is currently trading at $183.98, placing it 56.6% of the way from its 52-week low of $101.00 to its 52-week high of $247.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
| Industry | SERVICES-MISC HEALTH & ALLIED SERVICES, NEC |
| Employees | 78000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of DaVita Inc. (DVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.